Immunology deals with the physiological functioning of the immune system in states of both health and disease as well as malfunctions of the immune system in immunological disorders- With the new advancement in the immune sector- global pharmaceuticals continue to grow in the field despite the disruption during COVID-19. As in 2019- Abbvie again secured the top position with total revenue of $22.15B- followed by J&J- Roche- and Amgen
- Our team at PharmaShots has compiled a list of the top 20 immunology companies based on their 2020 immunology revenue
Immunology Segment Revenue: $0.015B
Founded Year: 1978
Market Cap: $0.067B
Total Employees: 185
Headquarters: New Jersey- United States
Stock Exchange: NASDAQ
Antares Pharma is a specialty pharmaceutical company focused primarily on the development & commercialization of pharmaceutical products and technologies addressing the unmet needs in the targeted therapeutic areas. The company has reported a total sale of $0.015B from its immunology segment in 2020 from the sales of Otrexup in RA- pJIA- Psoriasis.
Immunology Segment Revenue: $0.09B
Founded Year: 1993
Market Cap: $2.326B
Total Employees: 5,525
Headquarters: Shenyang- China
Stock Exchange: HKG
3S Bio is a Chinese Biotechnology company that focuses on oncology- nephrology- dermatology- and auto-immune diseases. The company unveiled total sales of $0.09B in its immunology segment during the year 2020 from the sales of Yisaipu- which is a TNF inhibitor indicated to treat RA- AS and psoriasis.
Immunology Segment Revenue: $0.99B
Founded Year: 2000
Market Cap: $100.73B
Total Employees: ~99,000
Headquarter: Brentford- United Kingdom
Stock Exchange: LON
GSK is a global healthcare multinational company involved in the development- manufacture- and marketing of pharmaceutical products- vaccines- OTC medicines- and health-related consumer products. With only approved products- Benlysta- GSK has generated a revenue of $0.99B in 2020. In Dec 2020- the US FDA has approved Benlysta as the first medicine for adult patients with active LN.
Immunology Segment Revenue: $1.05B
Founded Year: 2008
Market Cap: $23.61B
Total Employees: 1,600
Headquarters: Dublin- Ireland
Stock Exchange: NASDAQ
Horizon is a biopharmaceutical company that focuses on rare and rheumatic diseases. Horizon has generated the sale of $1.05B from its four approved immunology products including Tepezza- Rayos- Duexis- and Vimovo. During the fiscal year, 2020- Tepezza alone has generated $820M in revenue- followed by Duexis ($125.3M)- Rayos ($71.8M)- and Vimovo ($37.6M).
Immunology Segment Revenue: $1.08B
Founded Year: 2007
Market Cap: $42.9B
Total Employees: 6,805
Headquarters: Osaka- Japan
Stock Exchange: TYO
Mitsubishi Tanabe Pharma Corporation (MTPC) is a Japanese pharmaceutical company that focuses on diabetes- kidney diseases- autoimmune diseases- and vaccines. The company has reported a total sale of $1.08B from its immunology segment in 2020. In Dec’2020 MTPC initiates a long-term OLE trial to the phase III MT-1186-A03 trial of edaravone for Amyotrophic lateral sclerosis
Immunology Segment Revenue: $1.16B
Founded Year: 1891
Market Cap: $190.33B
Total Employees: 58,096
Headquarters: New Jersey- United States
Stock Exchange: NYSE
Merck & Co. is an American multinational pharmaceutical company. The company develops medicines (oncology- OTC- and generic drugs)- vaccines- biologic therapies- and animal health products. In 2020- Merck-approved drugs including Simponi and Remicade generated revenue of $1.16B.
Immunology Segment Revenue: $1.65B
Founded Year: 2005
Market Cap: $30.32B
Total Employees: 15,883
Headquarter: Tokyo- Japan
Stock Exchange: TYO
Astellas is a Japanese multinational pharmaceutical company. It focuses on serving patients’ medical needs across multiple therapeutic areas- including cardiology- hematology- immunology- infectious diseases- oncology- and urology. Astellas immune drug- Prograf generated revenue of $1.65B in 2020. In Jan 2020- Astellas announced the construction of a new manufacturing facility for Prograf’s API in the Toyama technology center.
Immunology Segment Revenue: $1.93B
Founded Year: 1991
Market Cap: $16.26B
Total Employees: 1,773
Headquarters: Delaware- United States
Stock Exchange: NASDAQ
Incyte is a global biopharmaceutical company that focuses on oncology- inflammation- and autoimmune diseases. In 2020- Incyte has generated revenue of $1.93B in its immunology segment. In Jul 2020- Incyte and MorphoSys announced that the FDA approved Monjuvi (tafasitamab-cxix)- which is indicated in combination with lenalidomide for R/R DLBCL
Immunology Segment Revenue: $1.94B
Founded Year: 1978
Market Cap: $50.50B
Total Employees: 9,100
Headquarter: Massachusetts- United States
Stock Exchange: NASDAQ
Biogen is a US-based biotechnology company that focuses on developing and delivering innovative therapies globally for neurological- neurodegenerative- and autoimmune diseases. Major areas of it include MS- neuroimmunology- neuromuscular disorders including Spinal Muscular Atrophy (SMA)- movement disorders including Parkinson’s disease- Ophthalmology- and neuropsychiatry. Biogen generated a revenue of $1.94 with Tysabri in the immunology segment. In Jun’2020- the company submitted the regulatory filing of Tysabri in the US and the EU.
Total Immunology Segment: $2.19B
Founded Year: 1928
Market Cap: $21.81B
Total Employees: 7,600
Headquarters: Brussels- Belgium
Stock Exchange: EBR
UCB is a multinational biopharmaceutical company that specializes in two therapeutic areas- the central nervous system (CNS) and immunology. Cimzia has generated total revenue of $2.1B in 2020. In Jan 2020- UCB’s biologic Cimzia (certolizumab pegol) was approved by MHRA for the treatment of PsO- PsA- pustular psoriasis- and psoriatic erythroderma for which existing treatment methods are not sufficiently effective. The approval makes Cimzia the first Fc-free- PEGylated anti-TNF treatment option in Japan.
Immunology Segment Revenue: $2.46B
Founded Year: 1876
Market Cap: $257.75B
Total Employees: 35,000
Headquarters: Indiana- United States
Stock Exchange: NYSE
Eli Lilly is an American pharmaceutical company focused on immunology- neurodegenerative diseases- and endocrinology. Eli Lilly has two approved immunology products including Olumiant and Taltz. Its immune product- Taltz has generated revenue of $1.78B while the remaining is from Olumiant’s sales in 2020. Taltz and Olumiant drove the 37% increase in revenue in Immunology.
Immunology Segment Revenue: $3.16B
Founded Year: 1887
Market Cap: $149.73B
Total Employees: 30,250
Headquarters: New York- United States
Stock Exchange: NYSE
BMS is a global biopharmaceutical company that focuses on multiple therapeutic areas including oncology- hematology- cardiovascular- and immunology. Its immune drug- Orencia generated revenue of $3.16 in 2020. The revenue of Orencia increased by 6% and 7% in the US and international markets due to higher demand respectively. In Jun’2020- the company reported results of an open-label P-IV Early AMPLE biomarker study assessing the differences by which Orencia and adalimumab interfere with disease progression in the mod. to sev. RA patients.
Immunology Segment Revenue: $3.56B
Founded Year: 1781
Market Cap: $51.87B
Total Employees: 47,495
Headquarter: Tokyo- Japan
Stock Exchange: TYO
Takeda is a Japanese multinational biopharmaceutical company. It is one of the top 20 largest pharmaceutical companies in the world by revenue. The company is focused on metabolic disorders- gastroenterology- neurology- inflammation- as well as oncology through its independent subsidiary. With Takeda’s immunology-approved drugs including Immunoglobulin and Albumin- Takeda has generated a $3.56B sale in 2020.
Immunology Segment Revenue: $4.56B
Founded Year: 1849
Market Cap: $269.75B
Total Employees: 78,500
Headquarters: New York- United States
Stock Exchange: NYSE
Pfizer is an American multinational pharmaceutical company. Pfizer develops and produces medicines and vaccines for immunology- oncology- cardiology- endocrinology- and neurology. Pfizer’s immune drug- Xeljanz generated revenue of $2.43B- followed by Enbrel ($1.35B) and inflectra ($0.65B) in 2020. In Sept 2020- the US FDA approved Xeljanz (tofacitinib) for the treatment of children and adolescents aged=2yrs. with active pcJIA.
Immunology Segment Revenue: $4.60B
Founded Year: 1973
Market Cap: $128.43B
Total Employees: 100-000
Headquarters: Paris- France
Stock Exchange: EPA
Sanofi is a French multinational pharmaceutical company. The company covers seven major therapeutic areas; cardiovascular- central nervous system- diabetes- internal medicine- oncology- thrombosis- and vaccines. Dupixent and Kevzara together contributed to the $4.60B revenue of the company in the immunology segment. In November 2020- Dupixent (dupilumab) was approved by European Commission as the first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis.
Immunology Segment Revenue: $4.86
Founded Year: 1996
Market Cap: $227.36B
Total Employees: 110,000
Headquarter: Basel- Switzerland
Stock Exchange: SWX
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel- Switzerland. It is one of the largest pharmaceutical companies in the world. The company is focused on immunology- Hepatology- Dermatology- oncology- Neurology- and Ophthalmology. Novartis immune drug- Cosentyx generated revenue of $3.9B and Ilaris generated 0.87B in 2020. Cosentyx received approval and launched in the EU and US for nr-axSpA- its fourth major indication- and in August became the first treatment approved in Japan for this indication. In April- Cosentyx also became the first IL17A inhibitor approved in China for the treatment of AS. In June- Ilaris was granted a new indication in the US for active Still’s disease including Adult-Onset Still’s Disease (AOSD).
Immunology Segment Revenue: $7.19B
Founded Year: 1980
Market Cap: $129.45B
Total Employees: 24,300
Headquarters: California- United States
Stock Exchange: NASDAQ
Amgen is an American multinational biopharmaceutical company that focuses on CV disease- oncology- bone health- neuroscience- immunology- nephrology- and inflammation. In 2020- Enbrel- a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis generated total sales of $4.9B whereas Otezla which is a PDE4 inhibitor generated a revenue of $2.1B.
Immunology Segment Revenue: $9.30B
Founded Year: 1896
Market Cap: $347.83B
Total Employees: 101,465
Headquarters: Basel- Switzerland
Stock Exchange: SWX
Roche is a Swiss multinational healthcare company. The immunology department of the company focuses on rheumatoid arthritis (RA)- systemic juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritis- and giant cell arteritis. Roche’s immunotherapies include Actemra- Xolair- Esbriet- MabThera- Pulmozyme- CellCept- and others. Actemra produces the highest revenue among all with $3.23B.
Immunology Segment Revenue: $15.05B
Founded Year: 1886
Market Cap: $457.45B
Headquarter: New Jersey- United States
Total Employees: 134,500
Stock Exchange: NYSE
Johnson and Johnson is an American multinational company that focuses on multiple therapeutic areas including Cardiovascular & Metabolism- Immunology- Infectious Diseases & Vaccines- Neuroscience- Oncology- and Pulmonary Hypertension. In its immunology segment- J&J focuses on core diseases like rheumatoid arthritis- inflammatory bowel diseases- and psoriasis. In 2020- its leading immunology product- Stelara generated sales of $7.70B- followed by Remicade- Simponi- and Tremfya with the revenue of $3.74B- $2.24B- and $1.34B respectively.
Immunology Segment Revenue: $22.15B
Founded Year: 2013
Market Cap: $200.96B
Total Employees: 48,000
Headquarters: Illinois- United States
Stock Exchange: NYSE
Abbvie is an American Biopharmaceutical company focused on the development of products in immunology- oncology- virology and neuroscience- dermatology. In Dec 2020- Abbvie announced that CHMP recommended the approval of Rinvoq for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult.
Related Post: Top 20 Immunology Companies Based 2019 Immunology Segment Revenue
